Phaseline

Companies › Almirall

Almirall: clinical trials, targets and expected readouts

6 active drug programs in 7 registered trials: 3 Phase 2, 2 Phase 3, 1 Phase 1, 1 Phase 4; Immunology, Other, Infectious disease; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tirbanibulin
Tyrosine-protein kinase SRC inhibitor
SRCPhase 4Keratosis, ActinicJul 2027
Lebrikizumab
Interleukin-13 inhibitor
IL13Phase 3Dermatitis, Atopic; Nummular EczemaApr 2027
LAD328
Unclear mechanism
–Phase 2Hidradenitis SuppurativaFeb 2027
LAD191–Phase 2Hidradenitis SuppurativaMay 2027
LAD603
JAK inhibitor
–Phase 2Alopecia AreataJun 2027
LAD106–Phase 1Healthy VolunteersMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07547813LAD328Phase 2Hidradenitis SuppurativaInfectious diseaseFeb 2027
NCT06526182LebrikizumabPhase 3Dermatitis, AtopicImmunologyApr 2027
NCT07151937LAD191Phase 2Hidradenitis SuppurativaImmunologyMay 2027
NCT07471932LAD106Phase 1Healthy VolunteersOtherMay 2027
NCT07311564LAD603Phase 2Alopecia AreataImmunologyJun 2027
NCT05387525TirbanibulinPhase 4Keratosis, ActinicImmunologyJul 2027
NCT07542483LebrikizumabPhase 3Nummular EczemaImmunologyAug 2028

Targets

IL13 (1) SRC (1)

Companies with the same targets

Eli Lilly Pfizer LEO Pharma AstraZeneca Nuvectis Pharma Turning Point Therapeutics The Skin Center Dermatology Group

Companies built like this

Spyre Therapeutics LEO Pharma Arthrosi Therapeutics Sunshine Guojian Pharmaceutical (Shanghai) MRM Health

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.